Physician profile
Jack L Berg
NPI 1639160021
$4,438.15
in general payments reported to CMS, 2019-2025
27 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $751 · 2021: $961 · 2022: $336 · 2023: $556 · 2024: $536 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $582.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $570.61 | 2019-2024 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $413.27 | 2019-2022 | |
| Pfizer INC. | $402.64 | 2019-2024 | |
| Novo Nordisk INC | $382.52 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.00 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $255.69 | 2019-2021 | |
| Abbvie INC. | $209.94 | 2020-2022 | |
| Glaxosmithkline, LLC. | $191.42 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $182.83 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $134.62 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $107.09 | 2019-2021 | |
| Astellas Pharma US INC | $91.15 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $75.40 | 2019-2022 | |
| Lundbeck LLC | $73.65 | 2023-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $68.78 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $60.43 | 2021 | |
| Acadia Pharmaceuticals INC | $42.42 | 2019-2020 | |
| Dexcom, INC. | $42.15 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $41.33 | 2019-2020 | |
| Eisai INC. | $34.07 | 2021 | |
| Amarin Pharma, INC. | $29.85 | 2019 | |
| Amgen INC. | $29.26 | 2024-2025 | Prolia, Evenity, Repatha |
| Paratek Pharmaceuticals, INC. | $21.11 | 2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $18.75 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $18.64 | 2019 | |
| Athena Bioscience, LLC | $14.86 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.